TOKYO–(BUSINESS WIRE)–Apr 4, 2019–Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug…Original Article
Kyowa Kirin Announces FDA Acceptance of Istradefylline (KW-6002) New Drug Application Resubmission in the US
